Latest Rituximab Stories
SEATTLE, Sept. 24, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the phase 1 study data of its highly selective oral JAK2 inhibitor pacritinib, or SB1518, showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed/refractory lymphoma. The results were published online in the Journal of Clinical Oncology in September, 2012. Thirty-four patients received daily oral doses of pacritinib ranging from...
SEATTLE, Sept. 11, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, today announced the initiation of the commercial launch of Pixuvri® in the European Union ("E.U.") with entry into Sweden, Denmark and Finland in September, to be followed by Austria and Norway in early October 2012 and Germany, United Kingdom and the Netherlands in November 2012. CTI plans to expand availability to...
SEATTLE, Aug. 1, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported financial results and recent accomplishments for the second quarter of 2012. Recent Company Highlights European Commission grants conditional marketing authorization for Pixuvri as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas ("NHL") Steven E. Benner, M.D., M.H.S. named new...
(Ivanhoe Newswire) - Each year an estimated 70,000 people globally are diagnosed with the kidney immune disorder, idiopathic membranous nephropathy (IMN). Idiopathic membranous nephropathy (IMN) can eventually lead to kidney failure. Standard therapies for IMN can be toxic and lead to further complications, but a new study has discovered the drug rituximab which is commonly used to treat lymphoma and arthritis also benefits patients with IMN. Standard therapy for IMN includes...
Rituximab is more effective and less toxic than standard therapies Highlights: Patients with a particular kidney immune disorder experienced remission when taking the immune drug rituximab, even when standard therapies had failed. Rituximab was safe and well-tolerated by all patients in the study. Each year, an estimated 70,000 people globally are diagnosed with the disorder, called idiopathic membranous nephropathy. A drug commonly used to treat immune disorders such as lymphoma...
SEATTLE, June 20, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, today announced that it is re-aligning its resources and re-prioritizing its product development pipeline to focus on the launch of Pixuvri in the EU and accelerate the advancement of pacritinib, CTI's recently-acquired, highly-selective JAK 2 inhibitor, into phase III clinical trials. As a result, CTI's operating...
AMSTERDAM, June 16, 2012 /PRNewswire/ -- Pharmacyclics, Inc (Nasdaq: PCYC) announced today at the 17th Congress of European Hematology Association updated results from two clinical trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). The ibrutinib clinical updates at EHA released in two oral presentations include: 1) updated safety and efficacy data from...
June 14, 2012, SEATTLE /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, today announced that former OncoMed Pharmaceuticals executive, Steven E. Benner, M.D., M.H.S., has joined CTI as Executive Vice President and Chief Medical Officer ("CMO"), reporting to James A. Bianco, M.D., Chief Executive Officer. Dr. Benner will take over all drug development activities at the company. Dr. Benner was...
BERLIN and BRUSSELS, June 8, 2012 /PRNewswire/ -- UCB today announced data from a post hoc analysis of the REALISTIC (RA Evaluation in Subjects Receiving TNF Inhibitor Certolizumab Pegol) study that were presented this week during the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Berlin, Germany, June 6-9, 2012. REALISTIC was a phase 3b study, consisting of a 12-week, randomized, double-blind, placebo-controlled phase followed by an...
Results of a separate study demonstrate that early and sustained remission are associated with decrease mortality According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with rheumatoid arthritis (RA) who are prescribed biologic treatments have a significantly lower mortality risk (adjusted hazard ratio [HR]: 0.61) than those just treated with traditional disease modifying anti-rheumatic drugs (DMARDs). The study also...
